Synthetic
peptides from the major envelope
protein of HTLV-I (ENV-I,
amino acid 177-213) and HTLV-II (ENV-II,
amino acid 173-209) and a conserved region of the transmembrane
protein (TM,
amino acid 378-402) were used as
antigens in microtiter plate
enzyme immunoassays (EIA) to detect and discriminate
antibodies to HTLV-I and II. The ENV-I and ENV-II
peptide EIAs were able to correctly discriminate HTLV-I and II
infections in 17 of 18 subjects whose
infections were determined by a gene amplification method. Sera from 100 of 107 subjects with serologically confirmed
infection with HTLV-I/II and 0 of 218 seronegative controls reacted with one or more of the
peptides (sensitivity, 93.5%; specificity, 100%). Ninety-six of the 100
peptide positive sera reacted exclusively with either the ENV-I or the ENV-II
peptide, thereby differentiating the two
viral infections. The pattern of reactivity to the ENV
peptides was distinct in different populations. Patients attending an Emergency Department, who had a history of
drug abuse, and male inmate entering a correctional facility only had antibody reactivity to the ENV-II
peptide. Subjects from Haiti and patients with HTLV-associated neurological disease only had antibody reactivity to the ENV-I
peptide.
Peptide-based
enzyme immunoassays that distinguish
antibodies to HTLV-I and HTLV-II will facilitate studies of the epidemiology of HTLV.